

# **LEBER'S HEREDITARY OPTIC** **NEUROPATHY**

## **ABOUT THE STUDY:**

Sponsored by Santhera Pharmaceuticals, the purpose of this multi-center study, called LEROS, is to assess the safety and effectiveness of long-term treatment with Idebenone (Raxone) in Leber's Hereditary Optic Neuropathy (LHON).

All participants enrolled will receive study treatment with Idebenone.

Participants participating in this study will have approximately 9 scheduled study visits over a period of 25 months. Each visit will last about 1-3 hours.

## **KEY INCLUSION CRITERIA:**

- Age  $\geq$  12 years
- Impaired visual acuity in affected eyes due to LHON
- Onset of symptoms  $\leq$  5 years

## **KEY EXCLUSION CRITERIA:**

- History of previous idebenone use
- Women who are pregnant or breastfeeding

---

## **FOR ADDITIONAL INFORMATION OR TO REFER A PATIENT, CONTACT:**

Principal Investigator: Steven Newman, MD

Study Coordinators: Ashton Leone, MPH, CCRP at (434) 243-5737 or [aml7q@virginia.edu](mailto:aml7q@virginia.edu)

Tamika Mercer, COA at (434) 243-2852 or [tmm2v@virginia.edu](mailto:tmm2v@virginia.edu)

Allison Weiderhold at (434) 243-2921 or [alw5rm@virginia.edu](mailto:alw5rm@virginia.edu)